Esophageal function and occurrence of Barrett's esophagus in Zollinger-Ellison syndrome
- PMID: 8549876
- DOI: 10.1159/000201258
Esophageal function and occurrence of Barrett's esophagus in Zollinger-Ellison syndrome
Abstract
Manifestations of esophageal disease are present in up to 60% of patients with Zollinger-Ellison syndrome (ZES), although esophageal function has been studied in only a few patients and the prevalence of Barrett's mucosa is unknown in these patients. It is unclear whether the high prevalence of esophageal disease is related to gastric acid hypersecretion alone or to abnormalities of esophageal motility or lower esophageal sphincter (LES) function in addition. To address these issues in the present study esophageal function was evaluated prospectively in 92 consecutive patients with ZES (66 with active disease, 26 disease-free after curative resection) seen during a 1-year period after controlling acid hypersecretion. In the patients with active disease the mean basal acid output (BAO) was 33 +/- 3.0 mEq/h, the maximal acid output (MAO) was 56 +/- 4.0 mEg/h, fasting serum gastrin was 8,736 +/- 4,813 pg/ml and duration of disease prior to study was 12.5 +/- 2.0 years. At the time of manometry, gastric acid secretion was controlled in all patients and no patient had evidence of gastroesophageal reflux disease at upper gastrointestinal endoscopy. Esophageal manometry revealed normal motility in 85% of patients. Eleven percent had low LES pressures, and only 1% of patients had an elevated LES pressure. The frequency of Barrett's mucosa (3%) was similar to that found in the general population but much less than that reported in patients with idiopathic GERD. No correlation was noted between LES pressures or manometric abnormalities and the fasting serum gastrin, BAO, MAO or the presence or absence of multiple endocrine neoplasia type I or previous vagotomy. Esophageal manometric results and LES pressure were similar in disease-free patients and those with active ZES. In conclusion, these results suggest that hypergastrinemia or other disease-specific abnormalities are not contributing to the high incidence of esophageal disease in patients with ZES because esophageal function in patients with ZES is similar to normals. Specifically, motility disorders in patients with ZES occur in similar frequency to normals, and LES pressure is normal in most patients. Despite the high levels of acid secretion and prominence of symptoms, the occurrence of Barrett's mucosa was uncommon (3%) raising the possibility of additional protective mechanisms in patients with ZES.
Similar articles
-
Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus.J Clin Endocrinol Metab. 2006 Jan;91(1):204-12. doi: 10.1210/jc.2005-1349. Epub 2005 Oct 25. J Clin Endocrinol Metab. 2006. PMID: 16249283
-
Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature.Medicine (Baltimore). 2001 May;80(3):189-222. doi: 10.1097/00005792-200105000-00005. Medicine (Baltimore). 2001. PMID: 11388095 Review.
-
Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.Gastroenterology. 1992 Mar;102(3):767-78. doi: 10.1016/0016-5085(92)90157-t. Gastroenterology. 1992. PMID: 1537514 Clinical Trial.
-
Basal and calcium-stimulated gastroesophageal sphincter pressure in patients with Zollinger-Ellison syndrome.Gastroenterology. 1977 Jun;72(6):1240-3. Gastroenterology. 1977. PMID: 858470
-
The diagnosis and management of Barrett's esophagus.Adv Surg. 1999;33:29-68. Adv Surg. 1999. PMID: 10572561 Review.
Cited by
-
Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion.Curr Gastroenterol Rep. 2004 Dec;6(6):454-63. doi: 10.1007/s11894-004-0067-5. Curr Gastroenterol Rep. 2004. PMID: 15527675 Review.
-
Effect of gastrin-17 on lower esophageal sphincter characteristics in man.Dig Dis Sci. 1997 Dec;42(12):2547-51. doi: 10.1023/a:1018872814428. Dig Dis Sci. 1997. PMID: 9440634 Clinical Trial.
-
Esophageal Perforation Unveiling the Diagnosis of Zollinger-Ellison Syndrome.J Community Hosp Intern Med Perspect. 2023 Sep 2;13(5):77-81. doi: 10.55729/2000-9666.1228. eCollection 2023. J Community Hosp Intern Med Perspect. 2023. PMID: 37868662 Free PMC article.
-
Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.Int J Mol Sci. 2019 Oct 16;20(20):5128. doi: 10.3390/ijms20205128. Int J Mol Sci. 2019. PMID: 31623145 Free PMC article. Review.
-
Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES.Cancers (Basel). 2023 Feb 21;15(5):1377. doi: 10.3390/cancers15051377. Cancers (Basel). 2023. PMID: 36900170 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources